Amgen reports positive results from Phase II study of bone cancer drug
Interim results from the 12-month, open-label Phase II study show that 120mg of denosumab, administered subcutaneously once monthly with a loading dose at days 8 and 15 of
Telix Pharmaceuticals has officially opened a radiopharmaceutical research, manufacturing, and treatment facility in Melbourne, Australia, to expedite the delivery of new treatments for cancer.
In this Roche-sponsored, placebo-controlled Phase III trial (Avado), two dose levels of Avastin in combination with docetaxel chemotherapy showed a statistically significant improvement in progression-free survival (PFS) compared